Packer M, Butler J, Zannad F, et al
[(2r)-2-acetoxy-3-carboxy-propyl]-trimethyl-ammonium 50
Progesterone resistance in endometriosis: current evidence and putative mechanisms
Sixty to eighty-five percent of patients improve with exposure-response prevention treatment, although for up to 30% of patients this treatment is not effective, or patients refuse or discontinue treatment due to the anxiety associated with the exposure (Grant 2014
PubMed , Biomedicines , vol
BPC-157 should not be used by people who are pregnant or breastfeeding, who have active cancer (it promotes angiogenesis), who are under 18, or who have a known allergy to it